Dyne Therapeutics (NASDAQ:DYN) Price Target Increased to $55.00 by Analysts at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN) had its price objective upped by HC Wainwright from $48.00 to $55.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q3 2024 earnings at ($0.77) EPS, Q4 2024 earnings at ($0.78) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.99) EPS, FY2027 earnings at ($1.34) EPS and FY2028 earnings at $0.71 EPS.

DYN has been the topic of a number of other research reports. Chardan Capital increased their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a buy rating in a research note on Tuesday, May 21st. Jefferies Financial Group upped their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a report on Monday, May 20th. JPMorgan Chase & Co. raised their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an overweight rating in a research note on Tuesday, July 9th. Morgan Stanley began coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They set an overweight rating and a $40.00 price target for the company. Finally, Oppenheimer reissued an outperform rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of Buy and a consensus target price of $50.60.

Dyne Therapeutics Trading Down 0.8 %

NASDAQ:DYN opened at $45.39 on Tuesday. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of -11.43 and a beta of 1.07. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $46.39. The company’s 50-day moving average is $38.62 and its two-hundred day moving average is $30.67.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics will post -3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 30,426 shares of Dyne Therapeutics stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the transaction, the insider now directly owns 149,647 shares of the company’s stock, valued at $4,932,365.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, insider Oxana Beskrovnaya sold 30,426 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the sale, the insider now directly owns 149,647 shares of the company’s stock, valued at $4,932,365.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $30.23, for a total transaction of $48,065.70. Following the sale, the senior vice president now owns 115,105 shares in the company, valued at approximately $3,479,624.15. The disclosure for this sale can be found here. Insiders have sold a total of 194,102 shares of company stock valued at $6,273,351 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $28,000. Amalgamated Bank increased its holdings in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $203,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after purchasing an additional 1,291 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.